Antibody-Drug Conjugates to Promote Immune Surveillance: Lessons Learned from Breast Cancer.

However, a numerical trend in favor of the combination was observed in the PD-L1 positive subgroup (HR for PFS 0.60; 95% CI 0.32–1.11; p = 0.099).

also in 227 other papers

In the subgroup defined as positive for PD-L1, treatment with atezolizumab plus T-DM1 showed a trend towards improved PFS compared to T-DM1 plus placebo.

also in 15,197 other papers